References
- Mor Z, Pinsker G. HIV/AIDS in Israel, epidemiological periodic report 1981–2009. Available at: http://www.health.gov.il/Download/pages/periodicReport2010.pdf.
- Kaplan EH, Kedem E, Pollack S. HIV incidence in Ethiopian immigrants to Israel. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:465–9.
- Etzioni A, Pollack S, Ben-Ishai Z. Prevention program of HIV infection in Ethiopian new immigrants to Israel. Acta Paediatr 1994;400:22–4.
- Chemtob D, Grossman Z. Epidemiology of adult and adolescent HIV infection in Israel: a country of immigration. Int J STD AIDS 2004;15:691–6.
- Kaplan EH, Soskolne V, Adler B, Leventhal A, Shtarkshall RA. A model- based evaluation of a cultural mediator outreach program for HIV+ Ethiopian immigrants in Israel. Eval Rev 2002;26:382–94.
- Soskolne V, Shtarkshall RA. Migration and HIV prevention programmes: linking structural factors, culture, and individual behaviour—an Israeli experience. Soc Sci Med 2002;55: 1297–307.
- Shtarkshall R, Soskolne V, Chemtov D, Rosen H. A culturally specific educational program to reduce the risk of HIV and HBV transmission among Ethiopian immigrants to Israel II: evaluating the effect of the training program on veteran immigrant trainees. Isr J Med Sci 1993;29:48–54.
- Chemtov D, Rosen H, Shtarkshall R, Soskolne V. A culturally specific educational program to reduce the risk of HIV and HBV transmission among Ethiopian immigrants to Israel: a preliminary report on training veteran immigrants as health educators. Isr J Med Sci 1993;29:437–42.
- Shtarkshall R. Migration populations and HIV/AIDS. The development and implantation of programmes: theory, methodology and practice. UNAIDS Best Practice. Geneva: UNESCO/UNAIDS; 2000.
- Romero-Ortuno R. Access to health care for illegal immigrants in the EU: should we be concerned? Eur J Health Law 2004;11:245–72.
- Pollard AJ, Savulescu J. Eligibility of overseas visitors and people of uncertain residential status for NHS treatment. Br Med J 2004;329:346–9.
- Chemtob D. Anti HIV treatment for pregnant women in Israel that are not insured by the national health insurance. Manifest of Israel Ministry of Health, Public health services, Department of Tuberculosis and AIDS. Jerusalem 2001.
- Campo RE, Alvarez D, Santos G, Latorre J. Antiretroviral treatment considerations in Latino patients. AIDS Patient Care STDs 2005;19:366–74.
- Page LC, Goldbaum G, Kent JB, Buskin SE. Access to regular HIV care and disease progression among black African immigrants. J Natl Med Assoc 2009;101:1230–6.
- Erwin J, Peters B. Treatment issues for HIV+ Africans in London. Soc Sci Med 1999;49:1519–28.
- Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, . Comparative response of African HIV-1 infected individuals to highly active antiretroviral therapy. AIDS 2002;16:1139–46.
- Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Møller A, . The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 35:1541–8.
- Staehelin C, Rickenbach M, Low N, Egger M, Ledergerber B, Hirschel B, . Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS 2003;17:2237–44.
- Pérez Molina JA, Rillo MM, Suárez-Lozano I, Casado Osorio JL, Cobo RT, González PR, . Do HIV-infected immigrants initiating HAART have poorer treatment-related outcomes than autochthonous patients in Spain? Results of the GESIDA 5808 Study. Curr HIV Res 2010;8:521–30.
- Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O’Shaughnessy MV, . Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568–77.
- Braithwaite RS, Roberts MS, Goetz MB, Gibert CL, Rodriguez- Barradas MC, Nucifora K, . Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence? Clin Infect Dis 2009;48:822–6.
- Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, . Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial. Lancet 2010;375:123–31.